Journal: Theranostics

Article Title: Silica Perturbs Primary Cilia and Causes Myofibroblast Differentiation during Silicosis by Reduction of the KIF3A-Repressor GLI3 Complex

doi: 10.7150/thno.37049

Figure Lengend Snippet: Detection of SHH signalling proteins in MRC-5 fibroblasts in response to SiO 2 stimulation and KIF3A knockdown. (A, B) Western blot and densitometric analyses of SHH, PTC1, SMO, and GLI1 proteins in MRC-5 fibroblasts treated with SiO 2 for 12 h together with KIF3A knockdown until 36 h. The relative density was normalised to α-Tub. Bar graphs are the means±SD of three separate experiments. * P <0.05; ** P <0.01. Data are the mean±SD. Statistical analysis was performed using one-way ANOVA and SPSS 20.0. (C) Schematic of the primary cilia influence on SHH signalling. Bidirectional transcriptional factors regulate the transcription of target genes.

Article Snippet: The cells were treated with 100 nmol/L of SMO agonist (SAG, CSN19210, CSNpharm, Chicago, IL, USA) for activating SHH signalling, 4 μg/L of specific GLI antagonist 61 (GANT61) (S8075, Selleckchem.com inhibitor expert, Munich, Germany) for inhibiting GLI1/2, and 20 μmol/L of GDC-0449 (S1082, Selleck, China) for inhibiting SMO .

Techniques: Knockdown, Western Blot

Journal: Theranostics

Article Title: Silica Perturbs Primary Cilia and Causes Myofibroblast Differentiation during Silicosis by Reduction of the KIF3A-Repressor GLI3 Complex

doi: 10.7150/thno.37049

Figure Lengend Snippet: KIF3a increases the stability of transcriptional repressor Gli3 R but not Gli3 FL in response to SMO activation. (A, B) Gli3 FL and Gli3 R protein levels in MRC-5 cells treated with SAG alone or SAG+GDC-0449 for the indicated periods of time. (C, D) Gli3 FL and Gli3 R protein levels in MRC-5 cells treated with SAG+ NC -cpDNA or SAG+ KIF3A -cpDNA for the indicated periods of time. (E, F) Gli3 FL and Gli3 R protein levels in MRC-5 cells treated with SAG+ NC -siRNA or SAG+ KIF3A -siRNA for the indicated periods of time. (G, H) Gli3 FL and Gli3 R protein levels in MRC-5 cells treated with CHX alone or CHX+ KIF3A -siRNA for the indicated periods of time. Levels of Gli3 FL and Gli3 R protein were measured by western blotting. α-Tub was used as a loading control. Scatter diagrams are the means±SD of three separate experiments.

Article Snippet: The cells were treated with 100 nmol/L of SMO agonist (SAG, CSN19210, CSNpharm, Chicago, IL, USA) for activating SHH signalling, 4 μg/L of specific GLI antagonist 61 (GANT61) (S8075, Selleckchem.com inhibitor expert, Munich, Germany) for inhibiting GLI1/2, and 20 μmol/L of GDC-0449 (S1082, Selleck, China) for inhibiting SMO .

Techniques: Activation Assay, Western Blot, Control

Journal: Molecular Medicine

Article Title: Smo gene silencing: a promising strategy for natural killer/t-cell lymphoma treatment via modulating proliferation and apoptosis

doi: 10.1186/s10020-025-01341-z

Figure Lengend Snippet: Effects of Smo activator and inhibitor on NKTCL cell proliferation and apoptosis. A, B Smo activity following treatment with different concentrations of SAG (A) or Cyclopamine (B), Smo activity (%) is shown relative to untreated SNT8 cells (set as 100%). C Cell proliferation assessed by CCK-8 assay. D, E Apoptosis analysis by flow cytometry, including quantification of apoptotic rates after SAG or Cyclopamine treatment. F Cell cycle distribution of SNT8, shCtrl SNT8, and shSmo SNT8 cells analyzed by PI staining. G Quantification of cell cycle phase distribution. H Nuclear morphology observed by DAPI staining. Data are presented as mean ± SE, n = 3. *Indicates a significant difference compared to the shCntrl group, with significant differences expressed as * p < 0.05, ** p < 0.01, *** p < 0.001. #Indicates a significant difference compared to the sh Smo group, with significant differences expressed as # p < 0.05, ## p < 0.01, ### p < 0.001. Statistical analysis was performed using one-way ANOVA

Article Snippet: Drug treatment: The Smo agonist SAG (566661, Merck, USA) was applied to the shSmo group, while the Smo inhibitor Cyclopamine (239803, Merck, USA) was used in the shControl group.

Techniques: Activity Assay, CCK-8 Assay, Flow Cytometry, Staining